Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.

The New England Journal of Medicine
Patrice SevereDaniel W Fitzgerald

Abstract

For adults with human immunodeficiency virus (HIV) infection who have CD4+ T-cell counts that are greater than 200 and less than 350 per cubic millimeter and who live in areas with limited resources, the optimal time to initiate antiretroviral therapy remains uncertain. We conducted a randomized, open-label trial of early initiation of antiretroviral therapy, as compared with the standard timing for initiation of therapy, among HIV-infected adults in Haiti who had a confirmed CD4+ T-cell count that was greater than 200 and less than 350 per cubic millimeter at baseline and no history of an acquired immunodeficiency syndrome (AIDS) illness. The primary study end point was survival. The early-treatment group began taking zidovudine, lamivudine, and efavirenz therapy within 2 weeks after enrollment. The standard-treatment group started the same regimen of antiretroviral therapy when their CD4+ T-cell count fell to 200 per cubic millimeter or less or when clinical AIDS developed. Participants in both groups underwent monthly follow-up assessments and received isoniazid and trimethoprim-sulfamethoxazole prophylaxis with nutritional support. Between 2005 and 2008, a total of 816 participants--408 per group--were enrolled and were fol...Continue Reading

References

Nov 5, 2002·Lancet·Daniel W FitzgeraldJean William Pape
Jul 2, 2004·The New England Journal of Medicine·Wafaie W FawziDavid J Hunter
Dec 2, 2005·The New England Journal of Medicine·Patrice SevereDaniel W Fitzgerald
Aug 30, 2007·The Journal of Infectious Diseases·Paul NunnKevin M De Cock
Aug 5, 2008·JAMA : the Journal of the American Medical Association·Scott M HammerUNKNOWN International AIDS Society-USA
Apr 3, 2009·The New England Journal of Medicine·Mari M KitahataUNKNOWN NA-ACCORD Investigators
Jul 22, 2009·Annals of Internal Medicine·Rochelle P WalenskyUNKNOWN CEPAC (Cost-Effectiveness of Preventing AIDS Complications)-International Investigators
Aug 21, 2009·The New England Journal of Medicine·Paul LegerDaniel W Fitzgerald

❮ Previous
Next ❯

Citations

Feb 11, 2011·Current Infectious Disease Reports·Frank S Rhame
Dec 7, 2011·Current Infectious Disease Reports·Bruce L GilliamZelalem Temesgen
Dec 14, 2011·Current Infectious Disease Reports·Katherine Huppler Hullsiek, Birgit Grund
Mar 8, 2014·The Lancet Infectious Diseases·Seonaid Nolan, Evan Wood
Jul 20, 2011·The New England Journal of Medicine·Myron S CohenUNKNOWN HPTN 052 Study Team
Feb 22, 2013·The New England Journal of Medicine·Kevin M De Cock, Wafaa M El-Sadr
Aug 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Paul E Sax
Dec 14, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Edward J Mills, Nathan Ford
Dec 17, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xavier AnglaretUNKNOWN ANRS 12222 Morbidity/Mortality Study Group
Mar 31, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Julia del AmoUNKNOWN HIV-CAUSAL Collaboration
Apr 5, 2012·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Raph L HamersUNKNOWN PharmAccess African Studies to Evaluate Resistance (PASER)
Mar 22, 2012·International Journal of Epidemiology·Matthew P FoxIan M Sanne
Mar 10, 2012·The Journal of Infectious Diseases·Kara M PalamountainGonzalo J Domingo
Dec 1, 2011·The Journal of Antimicrobial Chemotherapy·José A Pérez-MolinaSantiago Moreno
Jun 12, 2013·The Journal of Antimicrobial Chemotherapy·María Guzmán-FulgencioSalvador Resino
Jan 10, 2012·Current Opinion in HIV and AIDS·Myron S CohenTheresa R Gamble
Feb 25, 2011·Current Opinion in Pulmonary Medicine·Gregory CalligaroMarc Mendelson
Nov 10, 2010·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Roy M Gulick
Jun 10, 2011·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Stephen T WrightUNKNOWN Australian HIV Observational Database
Sep 14, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Wafaa M El-SadrAlan Whiteside
Jul 31, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Alexandra CoriaJean W Pape
Dec 18, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Susan A AdakunDavid R Bangsberg
Dec 21, 2012·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Edva NoelSerena P Koenig
Jun 13, 2013·Journal of Acquired Immune Deficiency Syndromes : JAIDS·Richard J LessellsMarie-Louise Newell
Oct 12, 2012·AIDS Research and Treatment·Akinsegun AkinbamiOlanrewaju Arogundade
Dec 3, 2011·Cancer Prevention Research·Daniel W FitzgeraldAndrew J Dannenberg
May 2, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Abdel G BabikerUNKNOWN INSIGHT START Study Group
Jun 14, 2012·Clinical Trials : Journal of the Society for Clinical Trials·Myron S CohenJeremy Sugarman
Sep 1, 2011·Therapeutic Advances in Chronic Disease·Mathias Lichterfeld, Kimon C Zachary
Apr 26, 2012·BMC Infectious Diseases·Alexandre GrangeiroJulio Cesar Rodrigues Pereira
Mar 1, 2012·BMC Clinical Pharmacology·George I EluwaChristoph Hamelmann
Dec 18, 2013·AIDS Research and Therapy·Denise C HsuJintanat Ananworanich

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antitubercular Agents (ASM)

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.

Antitubercular Agents

Antitubercular agents are pharmacologic agents for treatment of tuberculosis. Discover the latest research on antitubercular agents here.